BSX (Boston Scientific Corp.)
Insider Trading Activity
Every open-market purchase and sale reported by BSX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-26 | Susan E Morano | Director | Buy | — | — |
| 2026-08-12 | Emily Woodworth | SVP, Global Controller and CAO | I | — | — |
| 2026-08-11 | Jonathan Monson | EVP and CFO | I | — | — |
| 2026-08-07 | David C Habiger | Director | Buy | — | — |
| 2026-08-07 | David C Habiger | Director | Buy | — | — |
| 2026-08-05 | Michael F Mahoney | Chairman, President & CEO | MIXED | — | — |
| 2026-08-05 | David C Habiger | Director | Buy | — | — |
| 2026-08-03 | EDWARD J LUDWIG | Director | Buy | — | — |
| 2026-08-03 | Joseph Michael Fitzgerald | EVP & Group Pres, Cardiology | I | — | — |
| 2026-07-02 | Jonathan Monson | EVP and CFO | MIXED | — | — |
| 2026-06-01 | Michael F Mahoney | Chairman, President & CEO | G | — | — |
| 2026-05-21 | David C Habiger | Director | Buy | — | — |
| 2026-05-21 | EDWARD J LUDWIG | Director | Buy | — | — |
| 2026-05-21 | Cheryl Pegus | Director | Buy | — | — |
| 2026-05-11 | David C Habiger | Director | A | — | — |
| 2026-05-11 | EDWARD J LUDWIG | Director | A | — | — |
| 2026-05-11 | Jessica L Mega | Director | A | — | — |
| 2026-05-11 | Susan E Morano | Director | A | — | — |
| 2026-05-11 | Cheryl Pegus | Director | A | — | — |
| 2026-05-11 | Cathy R Smith | Director | A | — | — |
| 2026-05-11 | Christophe Pierre Weber | Director | A | — | — |
| 2026-05-11 | DAVID S WICHMANN | Director | A | — | — |
| 2026-05-11 | Ellen M Zane | Director | A | — | — |
| 2026-05-04 | Arthur C Butcher | EVP& Grp Pres, MedSurg & APAC | MIXED | — | — |
| 2026-05-04 | Padraig Andrew O'Connor | EVP, Global Operations | MIXED | — | — |
| 2026-03-04 | Cathy R Smith | Director | A | — | — |
| 2026-03-04 | Christophe Pierre Weber | Director | A | — | — |
| 2026-03-04 | Susan E Morano | Director | A | — | — |
| 2026-03-04 | Cheryl Pegus | Director | A | — | — |
| 2026-03-03 | Emily Woodworth | SVP, Global Controller and CAO | MIXED | — | — |
| 2026-02-27 | Arthur C Butcher | EVP& Grp Pres, MedSurg & APAC | I | — | — |
| 2026-02-18 | Vance R Brown | EVP, GC and Corp. Secretary | MIXED | — | — |
| 2026-02-18 | Arthur C Butcher | EVP& Grp Pres, MedSurg & APAC | MIXED | — | — |
| 2026-02-18 | Joseph Michael Fitzgerald | EVP & Group Pres, Cardiology | MIXED | — | — |
| 2026-02-18 | Michael F Mahoney | Chairman, President & CEO | MIXED | — | — |
| 2026-02-18 | Miriam O'Sullivan | SVP, Chief HR Officer | MIXED | — | — |
| 2026-02-18 | Jonathan Monson | EVP and CFO | MIXED | — | — |
| 2026-02-18 | Emily Woodworth | SVP, Global Controller and CAO | MIXED | — | — |
| 2026-02-18 | Padraig Andrew O'Connor | EVP, Global Operations | MIXED | — | — |
| 2026-02-17 | Vance R Brown | EVP, GC and Corp. Secretary | MIXED | — | — |
| 2026-02-17 | Arthur C Butcher | EVP& Grp Pres, MedSurg & APAC | MIXED | — | — |
| 2026-02-17 | Joseph Michael Fitzgerald | EVP & Group Pres, Cardiology | MIXED | — | — |
| 2026-02-17 | Michael F Mahoney | Chairman, President & CEO | MIXED | — | — |
| 2026-02-17 | Jonathan Monson | EVP and CFO | MIXED | — | — |
| 2026-02-17 | Padraig Andrew O'Connor | EVP, Global Operations | MIXED | — | — |
| 2026-02-17 | Emily Woodworth | SVP, Global Controller and CAO | MIXED | — | — |
| 2026-02-17 | Miriam O'Sullivan | SVP, Chief HR Officer | MIXED | — | — |
| 2026-02-03 | Michael F Mahoney | Chairman, President & CEO | MIXED | — | — |
| 2025-12-02 | Arthur C Butcher | EVP& Grp Pres, MedSurg & APAC | MIXED | — | — |
| 2025-12-01 | Miriam O'Sullivan | SVP, Chief HR Officer | G | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 54,635,185 | — |
| — | Director | 6,572,180 | — |
| — | Chairman, President & CEO | 1,612,143 | — |
| — | SVP Global Sales/Mkt CRM | 728,481 | — |
| — | President and CEO | 603,676 | — |
| — | President & CEO | 566,550 | — |
| — | — | 492,983 | — |
| — | EVP & President, Asia-Pacific | 447,631 | — |
| — | EVP & Chief Operations Officer | 432,240 | — |
| — | EVP | 250,869 | — |
| — | EVP and CFO | 232,618 | — |
| — | EVP & Group Pres, Cardiology | 219,141 | — |
| — | Chief Executive Officer | 180,828 | — |
| — | SVP & Pres, Neuromodulation | 177,258 | — |
| — | Director | 164,379 | — |
| — | EVP, GC & Chief Admin Officer | 154,681 | — |
| — | Director | 143,941 | — |
| — | EVP & President, MedSurg | 136,843 | — |
| — | EVP, Glob Ops, Qual & Tech | 128,517 | — |
| — | SVP, Asst GC, Bus & Regions | 125,690 | — |
| — | SVP & President, Europe | 116,025 | — |
| — | Director | 112,097 | — |
| — | EVP, Global Chief Med. Off. | 105,384 | — |
| — | EVP - Global Quality & Reg Aff | 86,624 | — |
| — | Director | 86,032 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BSX quote page; the site-wide leaderboard is on the insider transactions hub.